A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Phase 1

Completed

• Conditions: Advanced or Metastatic HCC
• Interventions: Drug: GC33

• Registration Number: NCT00746317
• Lead Sponsor: Chugai Pharmaceutical

Brief Summary

This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.

Detailed Description

This is a Phase I open-label dose escalation study of GC33 in patients with advanced or metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary assessment of anti-tumor activity. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-09-01
• Study First Submitted QC: 2008-09-02
• Study First Posted: 2008-09-03
• Primary Completion: 2010-10
• Status Verified: 2012-10
• Study Completion: 2012-10
• Last Update Submitted: 2012-10-15
• Last Update Posted: 2012-10-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved informed consent form

• Male or female ≥ 18 years old.

• Life expectancy ≥ 3 months.

• ECOG Performance Status of 0-1.

• Histologically confirmed hepatocellular carcinoma (without fibrolamellar subtype).

• Not a candidate for curative treatments.

• Child-Pugh A or B.

• Hematological, Biochemical and Organ Function:

  • AST (SGOT): ≤ 5.0 × ULN
  • ALT (SGPT): ≤ 5.0 × ULN
  • Total Bilirubin: ≤ 3.0 × ULN
  • Platelets: ≥ 50,000/μL
  • Absolute Neutrophil Count: ≥ 1,500/μL
  • Serum creatinine: ≤ 2.0 × ULN
  • PT-INR: ≤ 2.0,

• Ability to provide a tumor tissue sample either by:

  • a sample obtained within 3 months prior to informed consent for HCC diagnosis. Resection samples are not acceptable.
  • undergo a biopsy to confirm HCC diagnosis

• At least one measurable lesion based on Response Evaluation Criteria In Solid Tumors criteria.

(Extension Phase)

• Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved informed consent form.

• Male or female ≥ 18 years old.

• Life expectancy ≥ 3 months.

• ECOG Performance Status of 0-1.

• Histologically confirmed hepatocellular carcinoma (without fibrolamellar subtype).

• Not a candidate for curative treatments.

• Child-Pugh A.

• Hematological, Biochemical and Organ Function:

  • AST (SGOT): ≤ 5.0 × ULN
  • ALT (SGPT): ≤ 5.0 × ULN
  • Total Bilirubin: ≤ 3.0 × ULN
  • Platelets: ≥ 50,000/μL
  • Absolute Neutrophil Count: ≥ 1,500/μL
  • Serum creatinine: ≤ 2.0 × ULN
  • PT-INR: ≤ 2.0

• IHC confirmed GPC3-positive HCC tumor tissue. Tumor tissue sample may be provided by:

  • A formalin fixed paraffin embedded block sample within 12 months prior to informed consent for HCC diagnosis;
  • Unstained slides obtained within 3 months prior to informed consent for HCC diagnosis;
  • Undergo biopsy to confirm GPC3-positive HCC.
  • Resection samples are not acceptable.

• At least one measurable lesion based on Response Evaluation Criteria In Solid Tumors criteria.

Exclusion Criteria

• Child-Pugh C.

• Pregnant or lactating women or women of child-bearing potential and men of childbearing potential not willing to use effective means of contraception.

• Patients known to be positive for Human immunodeficiency virus infection.

• Active infectious diseases requiring treatment except for hepatitis B and C.

• Other malignancies within the last 5 years.

• History of transplantation (organ, bone marrow transplantation,peripheral blood stem cell transplantation, etc.).

• Patients with significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug.

• Patients with brain metastases, other central nervous system or other psychiatric disease.

• Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1.

• Patients who received the following treatments within 2 weeks prior to Day1:

  • Anticoagulant or thrombolytic agents for therapeutic purposes.
  • Systemic anti-viral therapy for hepatitis C/cirrhosis.
  • Blood transfusion

• History of hypersensitivity to similar agents.

• Patient is unable to comply with the requirements of the protocol and/or follow-up procedures.

(Extension Phase)

• Child-Pugh B or C.

• Pregnant or lactating women or women of child-bearing potential and men of childbearing potential not willing to use effective means of contraception.

• Patients known to be positive for Human immunodeficiency virus infection.

• Active infectious diseases requiring treatment except for hepatitis B and C.

• Other malignancies within the last 5 years.

• History of transplantation (organ, bone marrow transplantation, Peripheral blood stem cell transplantation, etc.).

• Patients with significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug.

• Patients with brain metastases, other central nervous system or other psychiatric disease.

• Patients who received major surgery, local therapy for HCC, chemotherapy, radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4 weeks prior to Day 1.

• Patients who received the following treatments within 2 weeks prior to Day 1:

  • Anticoagulations or thrombolytic agents for therapeutic purposes.
  • Systemic anti-viral therapy for hepatitis C/cirrhosis.
  • Blood transfusion

• History of hypersensitivity to similar agents.

• Patient is unable to comply with the requirements of the protocol and/or follow-up procedures.

• IHC confirmed GPC3-negative HCC tumor tissue.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	GC33	-

Primary Outcome Measures

Name	Time	Method
Determine the safety and tolerability of escalating doses of GC33	Continuously

Secondary Outcome Measures

Name	Time	Method
Characterize the pharmacokinetics of GC33	Continuously
Perform a preliminary assessment of anti-tumor activity of GC33	Continuously

Trial Locations

Locations (9)

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Karmanos Cancer Center at the Detroit Medical Center; 🇺🇸 Detroit, Michigan, United States

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Swedish Cancer Institute at the Swedish Medical Center; 🇺🇸 Seattle, Washington, United States

Washington University; 🇺🇸 St. Louis, Missouri, United States

Columbia University Medical Center; 🇺🇸 New York, New York, United States

Methodist Hospital; 🇺🇸 Houston, Texas, United States

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States